Sugentech Inc. (KOSDAQ:253840)

Market Cap	116.81B
Revenue (ttm)	10.03B
Net Income (ttm)	-14.36B
Shares Out	15.29M
EPS (ttm)	-942.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	338,648
Average Volume	3,105,342
Open	7,640.00
Previous Close	7,640.00
Day's Range	7,330.00 - 7,640.00
52-Week Range	4,700.00 - 11,500.00
Beta	0.95
RSI	55.61
Earnings Date	May 13, 2025

About Sugentech

Sugentech Inc. develops and sells in-vitro diagnostic systems and products based on biotechnology, information technology, and nanotechnology in South Korea and internationally. The company offers lab tests, including systems and test items; and COVID-19 tests. It also provides point of care testing analyzers and test items for testing of influenza A/B, antibody test, COVID-19 and flu, SARS-CoV-2, HbA1c, beta-hcg, YSH, T3/T4, and CRP; and digital health and home tests, including mobile health, ovulation, and pregnancy products. The company was ...

• Industry: Medical - Specialties
• Sector: Healthcare
• Founded: 2011
• Employees: 145
• Stock Exchange: KOSDAQ
• Ticker Symbol: 253840

Financial Performance

In 2024, Sugentech's revenue was 10.10 billion, an increase of 41.57% compared to the previous year's 7.13 billion. Losses were -15.19 billion, -11.87% less than in 2023.